Advertisement

Topics

Loxo, Bayer to co-develop cancer drugs in up to $1.55 billion deal

07:53 EST 14 Nov 2017 | Reuters

(Reuters) - Loxo Oncology Inc will collaborate with Germany's Bayer AG to develop and commercialize two of its cancer therapies, the companies said on Tuesday, in deal that could bring the U.S. drug developer up to $1.55 billion.

Original Article: Loxo, Bayer to co-develop cancer drugs in up to $1.55 billion deal

NEXT ARTICLE

More From BioPortfolio on "Loxo, Bayer to co-develop cancer drugs in up to $1.55 billion deal"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...